2017 Q2 Form 10-Q Financial Statement

#000114420417043149 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $640.0K $830.0K $830.0K
YoY Change -22.89% -16.16% -13.54%
% of Gross Profit
Research & Development $435.0K $151.0K $990.0K
YoY Change 188.08% -89.02% -20.48%
% of Gross Profit
Depreciation & Amortization $18.00K $22.00K $16.00K
YoY Change -18.18% -26.67% -20.0%
% of Gross Profit
Operating Expenses $435.0K $151.0K $1.810M
YoY Change 188.08% -89.02% -17.91%
Operating Profit -$1.075M -$983.0K -$1.812M
YoY Change 9.36% -58.4% -17.82%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $40.00K $20.00K $20.00K
YoY Change 100.0% -80.0% -166.67%
Pretax Income -$1.040M -$960.0K -$1.790M
YoY Change 8.33% -57.71% -20.09%
Income Tax
% Of Pretax Income
Net Earnings -$1.040M -$962.0K -$1.790M
YoY Change 8.11% -57.53% -19.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$55.50K -$51.47K -$95.98K
COMMON SHARES
Basic Shares Outstanding 18.74M shares 18.65M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q2 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.720M $11.48M $12.95M
YoY Change -41.46% -41.73% -39.34%
Cash & Equivalents $5.784M $944.0K $2.213M
Short-Term Investments $930.0K $10.54M $10.73M
Other Short-Term Assets $230.0K $70.00K $80.00K
YoY Change 228.57% -36.36% 100.0%
Inventory
Prepaid Expenses
Receivables $740.0K $1.270M $480.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.680M $12.81M $13.51M
YoY Change -40.05% -36.14% -38.81%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $318.0K $281.0K
YoY Change -5.66% 12.77% -3.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $341.0K $304.0K
YoY Change -94.13% 1605.0% 1420.0%
Total Long-Term Assets $320.0K $344.0K $304.0K
YoY Change -6.98% 13.53% -1.62%
TOTAL ASSETS
Total Short-Term Assets $7.680M $12.81M $13.51M
Total Long-Term Assets $320.0K $344.0K $304.0K
Total Assets $8.000M $13.15M $13.81M
YoY Change -39.18% -35.4% -38.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $230.0K $355.0K $281.0K
YoY Change -35.21% -52.98% -69.52%
Accrued Expenses $114.0K $652.0K $675.0K
YoY Change -82.52% -56.68% -57.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $711.0K $1.282M $1.242M
YoY Change -44.54% -49.25% -54.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $711.0K $1.282M $1.242M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $710.0K $1.280M $1.240M
YoY Change -44.53% -49.33% -54.51%
SHAREHOLDERS EQUITY
Retained Earnings -$77.95M -$72.89M -$71.93M
YoY Change 6.93% 10.19% 12.59%
Common Stock $11.00K $84.75M $11.00K
YoY Change -99.99% -99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.290M $11.87M $12.57M
YoY Change
Total Liabilities & Shareholders Equity $8.000M $13.15M $13.81M
YoY Change -39.18% -35.39% -38.31%

Cashflow Statement

Concept 2017 Q2 2016 Q2 2016 Q1
OPERATING ACTIVITIES
Net Income -$1.040M -$962.0K -$1.790M
YoY Change 8.11% -57.53% -19.95%
Depreciation, Depletion And Amortization $18.00K $22.00K $16.00K
YoY Change -18.18% -26.67% -20.0%
Cash From Operating Activities -$1.630M -$1.410M -$2.980M
YoY Change 15.6% -14.55% 53.85%
INVESTING ACTIVITIES
Capital Expenditures $32.00K $59.00K $26.00K
YoY Change -45.76% -468.75%
Acquisitions
YoY Change
Other Investing Activities $6.810M $200.0K $4.790M
YoY Change 3305.0% -137.74% -135.3%
Cash From Investing Activities $6.780M $130.0K $4.770M
YoY Change 5115.38% -123.64% -135.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $30.00K 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -$1.630M -1.410M -2.980M
Cash From Investing Activities $6.780M 130.0K 4.770M
Cash From Financing Activities $30.00K 0.000 0.000
Net Change In Cash $5.180M -1.280M 1.790M
YoY Change -504.69% -41.55% -336.46%
FREE CASH FLOW
Cash From Operating Activities -$1.630M -$1.410M -$2.980M
Capital Expenditures $32.00K $59.00K $26.00K
Free Cash Flow -$1.662M -$1.469M -$3.006M
YoY Change 13.14% -10.1% 55.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
370000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
711000 USD
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
114000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
11000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77948000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
14128000 USD
CY2016 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
121000 USD
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
635000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
183000 USD
us-gaap Depreciation
Depreciation
34000 USD
us-gaap Depreciation
Depreciation
38000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3272000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4387000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
183000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
465000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
31000 USD
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
511000 USD
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
499000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-118000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-814000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-35000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
85000 USD
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-8510000 USD
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-4990000 USD
bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
-1000 USD
bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
2000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8479000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4903000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
30000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5237000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
516000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
428000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-856000 USD
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
944000 USD
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
183000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
496000 USD
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18747327 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18687987 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18747327 shares
bcli Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05 pure
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03 pure
us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P1M
CY2016 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P5M
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4900000 USD
CY2009Q4 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
74667 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18687987 shares
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
435000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
640000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
832000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1075000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-983000 USD
CY2017Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-35000 USD
CY2016Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-21000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1040000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-962000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.06
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.05
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18738496 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18654040 shares
CY2016Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-34000 USD
CY2016Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
46600000 USD
CY2016Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
74000 USD
CY2017Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000 USD
CY2016Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000 USD
CY2017Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-6810000 USD
CY2016Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-196000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14246831 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4489973 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3808654 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5948202 shares
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
57000 USD
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
262000 USD
CY2017Q2 us-gaap Depreciation
Depreciation
18000 USD
CY2016Q2 us-gaap Depreciation
Depreciation
22000 USD
CY2017Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2017Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
57000 USD
CY2016Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
262000 USD
CY2017Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
57000 USD
CY2017Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1630000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1406000 USD
CY2017Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
587000 USD
CY2016Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
768000 USD
CY2017Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-135000 USD
CY2017Q2 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
-2000 USD
CY2016Q2 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
0 USD
CY2017Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6780000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
137000 USD
CY2017Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
30000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2017Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
604000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1269000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5180000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2213000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2017Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 56.7pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="76"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 28.35pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="38"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt"> D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of estimates</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 1.25in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-17-043149-index-headers.html Edgar Link pending
0001144204-17-043149-index.html Edgar Link pending
0001144204-17-043149.txt Edgar Link pending
0001144204-17-043149-xbrl.zip Edgar Link pending
bcli-20170630.xml Edgar Link completed
bcli-20170630.xsd Edgar Link pending
bcli-20170630_cal.xml Edgar Link unprocessable
bcli-20170630_def.xml Edgar Link unprocessable
bcli-20170630_lab.xml Edgar Link unprocessable
bcli-20170630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v472033_10q.htm Edgar Link pending
v472033_ex31-1.htm Edgar Link pending
v472033_ex31-2.htm Edgar Link pending
v472033_ex32-1.htm Edgar Link pending
v472033_ex32-2.htm Edgar Link pending